[The relation between myelotoxicity and performance status or aging in chemotherapy of non-small cell lung cancer].
One hundred eighty six patients of non-small cell lung cancer treated with cisplatin-based chemotherapy were analyzed. Significant incidence of anemia was observed in PS 2-3 patients as compared to PS 0-1 cases. Incidence of thrombocytopenia was significant in cases 70 or more years old as compared those less than 50 years old. No correlation was detected between myelotoxicity and aging.
Oshita
F
F
Department of Internal Medicine, National Cancer Center Hospital, Tokyo.
Shinkai
T
T
Miya
T
T
Kojima
A
A
Ohe
Y
Y
Tamura
T
T
Sasaki
Y
Y
Eguchi
K
K
Saijo
N
N
D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001853:Bone Marrow / Q000187:drug effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D013921:Thrombocytopenia / Q000139:chemically induced*; D014751:Vindesine / Q000008:administration & dosage
D008937:Mitomycins; D016685:Mitomycin; D002945:Cisplatin; D014751:Vindesine